Novo Nordisk disclosed that two large Phase III trials testing oral semaglutide in early Alzheimer’s disease failed to slow clinical progression versus placebo. The Evoke and Evoke+ studies enrolled nearly 3,800 patients with biomarker‑confirmed amyloid pathology and found no cognitive or functional benefit on standard endpoints. Novo said biomarker changes were observed but did not translate into clinical improvement. The negative outcome curtails hopes that GLP‑1 receptor agonists could deliver a disease‑modifying effect in Alzheimer’s and is likely to reshape investment and research priorities around incretin biology for neurodegeneration.